Improved hygiene leading to reduced exposure to microorganisms has been implicated as one possible cause for the recent "epidemic" of chronic inflammatory diseases (CIDs) in industrialized countries. That is the essence of the hygiene hypothesis that argues that rising incidence of CIDs may be, at least in part, the result of lifestyle and environmental changes that have made us too "clean" for our own good, so causing changes in our microbiota. Apart from genetic makeup and exposure to environmental triggers, inappropriate increase in intestinal permeability (which may be influenced by the composition of the gut microbiota), a "hyper-belligerent" immune system responsible for the tolerance-immune response balance, and the composition of gut microbiome and its epigenetic influence on the host genomic expression have been identified as three additional elements in causing CIDs. During the past decade, a growing number of publications have focused on human genetics, the gut microbiome, and proteomics, suggesting that loss of mucosal barrier function, particularly in the gastrointestinal tract, may substantially affect antigen trafficking, ultimately influencing the close bidirectional interaction between gut microbiome and our immune system. This cross-talk is highly influential in shaping the host gut immune system function and ultimately shifting genetic predisposition to clinical outcome. This observation led to a re-visitation of the possible causes of CIDs epidemics, suggesting a key pathogenic role of gut permeability. Pre-clinical and clinical studies have shown that the zonulin family, a group of proteins modulating gut permeability, is implicated in a variety of CIDs, including autoimmune, infective, metabolic, and tumoral diseases. These data offer novel therapeutic targets for a variety of CIDs in which the zonulin pathway is implicated in their pathogenesis.
Keywords: Chronic inflammatory diseases; Gut permeability; microbiome; zonulin.
Copyright: © 2020 Fasano A.
Conflict of interest statement
Competing interests: The author is co-founder and stock holder of Alba Therapeutics, a company developing treatments complementary to the gluten-free diet by exploiting gut permeability.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.
Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments.Dig Dis Sci. 2019 Jul;64(7):1748-1758. doi: 10.1007/s10620-019-05646-y. Dig Dis Sci. 2019. PMID: 31076989 Review.
Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model.Ann N Y Acad Sci. 2017 Jun;1397(1):130-142. doi: 10.1111/nyas.13343. Epub 2017 Apr 19. Ann N Y Acad Sci. 2017. PMID: 28423466 Free PMC article.
Zonulin as a potential putative biomarker of risk for shared type 1 diabetes and celiac disease autoimmunity.Diabetes Metab Res Rev. 2020 Mar 12:e3309. doi: 10.1002/dmrr.3309. Online ahead of print. Diabetes Metab Res Rev. 2020. PMID: 32162764 Review.
Exploiting the Zonulin Mouse Model to Establish the Role of Primary Impaired Gut Barrier Function on Microbiota Composition and Immune Profiles.Front Immunol. 2019 Sep 19;10:2233. doi: 10.3389/fimmu.2019.02233. eCollection 2019. Front Immunol. 2019. PMID: 31608059 Free PMC article.
Gut Microbiota Richness and Composition and Dietary Intake of Overweight Pregnant Women Are Related to Serum Zonulin Concentration, a Marker for Intestinal Permeability.J Nutr. 2016 Sep;146(9):1694-700. doi: 10.3945/jn.116.235358. Epub 2016 Jul 27. J Nutr. 2016. PMID: 27466607